Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
"Only a patient can really appreciate how much ringing the bell matters. So the day he hung it up, it was the most joyous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback